Phase 3 Readout Calendar
Industry-sponsored trials with primary completion in the next 12 months or last 12 months.
Data last updated November 12, 2026 · source: ClinicalTrials.gov
469
Next 6 months
847
Next 12 months
295
Results posted
909
Stale estimates
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 trial reading out in the next 12 months — searchable by sponsor, indication, or NCT, with a per-row staleness flag so you know which dates are still credible.
What's reading out at AstraZeneca in the next 6 months?
Filter by sponsor, then set the window to Next 6 months — it reveals a company's full near-term catalyst slate on one screen.
Which trials are completed but topline isn't out yet?
Filter confidence to “Completed · awaiting.” These are imminent or already-announced reads sitting in the FDAAA 12-month results-posting window.
Are there any GLP-1 or obesity Phase 3 readouts coming up?
Search “obesity” or “GLP-1” in the filter box, and combine with a sponsor such as Lilly or Novo Nordisk for tighter cuts.
Which sponsor-estimated dates haven't been updated in 12+ months?
Filter confidence to “Estimated · stale.” These are the dates most likely to slip — useful for watchlist hygiene and short-thesis scouting.
What's reading out in a specific quarter, like Q2 2026?
Use the window filter (Next 3 / 6 / 12 months) and combine with confidence to shortlist near-term, high-confidence catalysts.
Did a specific trial (NCT ID) read out yet?
Search by NCT ID. The confidence label tells you “Read out” (results posted) vs “Completed · awaiting” vs an estimated date.
Recently read-out results are free; the upcoming calendar shows a free preview, and filters are Pro. How we anchor dates & what we don't claim →
Browse by therapeutic area
Expected to have read out
· 219Industry Phase 3 trials whose estimated primary completion has passed in the last 3 months but CT.gov has not confirmed it — topline may be imminent, or the date may have slipped. Unconfirmed; most recently expected first.
Estimated completion has passed but CT.gov hasn't confirmed — topline may be imminent, or the date slipped · most recent: Hoffmann-La Roche (2026-11-12)
| Sponsor | Trial / Asset | Indication | Results | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Q4 2026 · 124 | ||||||
| Hoffmann-La Roche | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis Asset: Ocrelizumab | Progressive Multiple Sclerosis (PMS) | est. due Nov 2027 | Q4 2026 2026-11-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT03523858 |
| Qilu Pharmaceutical Co., Ltd. | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Asset: Relugolix | Heavy Menstrual Bleeding +1 | est. due Nov 2027 | Q4 2026 2026-11-12 (est.) | Estimated · aging
Updated 9mo ago
| NCT06671548 |
| Janssen Research & Development, LLC | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE Asset: Milvexian | Ischemic Stroke; Ischemic Attack, Transient | est. due Nov 2027 | Q4 2026 2026-11-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT05702034 |
| Tasly Pharmaceutical Group Co., Ltd | Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) Asset: Changkang granules | Diarrhea-predominant Irritable Boewl Syndrome | est. due Nov 2027 | Q4 2026 2026-11-11 (est.) | Estimated · stale
Updated 22mo ago
| NCT06753890 |
| LaNova Medicines Zhejiang Co., Ltd. | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. Asset: LM-302 | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | est. due Nov 2027 | Q4 2026 2026-11-10 (est.) | Estimated · aging
Updated 9mo ago
| NCT06351020 |
| Gan & Lee Pharmaceuticals. | A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin Asset: GZR4 | Diabetes | est. due Nov 2027 | Q4 2026 2026-11-10 (est.) | Estimated · aging
Updated 12mo ago
| NCT07165223 |
| LEAF4Life, Inc. | Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome Asset: LEAF-4L6715 | Acute Respiratory Distress Syndrome | est. due Nov 2027 | Q4 2026 2026-11-09 (est.) | Estimated · stale
Updated 25mo ago
| NCT06640777 |
| Novartis Pharmaceuticals | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up Asset: LOU064 (blinded) | Chronic Spontaneous Urticaria | est. due Nov 2027 | Q4 2026 2026-11-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT05677451 |
| Genzyme, a Sanofi Company | Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX Asset: Fitusiran | Hemophilia | est. due Nov 2027 | Q4 2026 2026-11-05 (est.) | Estimated · aging
Updated 11mo ago
| NCT03754790 |
| CMG Pharmaceutical Co. Ltd | Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia Asset: CMG190303(Dapagliflozin/Rosuvastatin) | Dyslipidemia +1 | est. due Nov 2027 | Q4 2026 2026-11-04 (est.) | Estimated · aging
Updated 10mo ago
| NCT06772168 |
| Bristol-Myers Squibb | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) Asset: KarXT | Bipolar Disorder Type I With Mania or Mania With Mixed Features | est. due Nov 2027 | Q4 2026 2026-11-02 (est.) | Estimated · aging
Updated 7mo ago
| NCT06951711 |
| Epygenix | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Asset: Clemizole HCl | Lennox Gastaut Syndrome | est. due Nov 2027 | Q4 2026 2026-11-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT05066217 |
| Bristol-Myers Squibb | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Asset: KarXT | Bipolar-I Disorder With Mania or Mania With Mixed Features | est. due Nov 2027 | Q4 2026 2026-11-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT06951698 |
| Scholar Rock, Inc. | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab Asset: Apitegromab | Spinal Muscular Atrophy +9 | est. due Nov 2027 | Q4 2026 2026-11-01 (est.) | Estimated · stale
Updated 18mo ago
| NCT05626855 |
| Arthrosi Therapeutics | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) Asset: AR882 50 mg | Gout +3 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 19mo ago
| NCT06439602 |
| Eli Lilly and Company | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Asset: Tirzepatide | Type 1 Diabetes +2 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 9mo ago
| NCT06914895 |
| Sichuan Kelun-Biotech Biopharmaceu… | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: SKB264 | Non-Small Cell Lung Cancer | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT06448312 |
| Definium Therapeutics US, Inc. | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Asset: DT120 | Generalized Anxiety Disorder | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT06809595 |
| Seqirus | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age Asset: aQIV or aTIV | Influenza, Human | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT06087640 |
| Sichuan Baili Pharmaceutical Co., … | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) Asset: BL-B01D1 | Nasopharyngeal Carcinoma | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT06118333 |
| SK Life Science, Inc. | Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures Asset: Xcopri | Partial Epilepsy | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT05067634 |
| Sinovac Biotech Co., Ltd | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years Asset: experimental vaccine | Epidemic Meningitis +1 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 7mo ago
| NCT07505888 |
| DBV Technologies | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Allergy +1 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT07003919 |
| Definium Therapeutics US, Inc. | A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Asset: DT120 | Major Depressive Disorder | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT06941844 |
| AbbVie | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease Asset: ABBV-444 | Dry Eye Disease | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 8mo ago
| NCT07284381 |
| Immunic AG | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Asset: IMU-838 tablets | Multiple Sclerosis | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 9mo ago
| NCT05134441 |
| Immunic AG | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Asset: IMU-838 tablets | Multiple Sclerosis, Relapsing-Remitting | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 9mo ago
| NCT05201638 |
| Eli Lilly and Company | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Asset: Tirzepatide | Type 1 Diabetes +2 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 9mo ago
| NCT06962280 |
| Wooshin Labottach Co., Ltd. | Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis | Nail Psoriasis +2 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 10mo ago
| NCT07029516 |
| Nuance Hearing | A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy | Hearing Loss Mixed | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 11mo ago
| NCT07282028 |
| Waterstone Pharmaceutical (Wuhan) … | A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia Asset: WS016 | Hyperkalemia | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 12mo ago
| NCT07251309 |
| Lynk Pharmaceuticals Co., Ltd | A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis Asset: LNK01001 | Ankylosing Spondylitis | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 12mo ago
| NCT07237568 |
| Medicure | Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency Asset: Pyridoxal Phosphate | Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 13mo ago
| NCT04706013 |
| Eli Lilly and Company | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Asset: Orforglipron | OSA +1 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 13mo ago
| NCT06649045 |
| Nanjing Chia-tai Tianqing Pharmace… | A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Asset: NTQ5082 capsules 200 mg | Paroxysmal Nocturnal Hemoglobinuria | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 14mo ago
| NCT07177859 |
| medac GmbH | Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. Asset: Methotrexate | Moderate to Severe Atopic Dermatitis | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 15mo ago
| NCT06239311 |
| LG Chem | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series Asset: LBVD | Diphtheria +5 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 16mo ago
| NCT06947499 |
| Cambium Bio Limited | Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye Asset: CAM-101 | Dry Eye Disease +3 | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 18mo ago
| NCT06903611 |
| Qilu Pharmaceutical Co., Ltd. | Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer Asset: QLG1080 | Prostate Cancer | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 21mo ago
| NCT06837896 |
| Akeso | A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma Asset: cadonilimab | Gastric and Gastroesophageal Junction Adenocarcinoma | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 29mo ago
| NCT06341335 |
| NewAmsterdam Pharma | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease Asset: Obicetrapib | Atherosclerotic Cardiovascular Disease | est. due Nov 2027 | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 29mo ago
| NCT05202509 |
| Janssen Research & Development, LLC | A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation Asset: Milvexian | Atrial Fibrillation | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05757869 |
| Viatris Innovation GmbH | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus Asset: Cenerimod | Lupus Erythematosus, Systemic | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05648500 |
| Teva Branded Pharmaceutical Produc… | A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations Asset: TEV-56248 | Asthma | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06052267 |
| Annexon, Inc. | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Asset: Vonaprument | Geographic Atrophy | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 12mo ago
| NCT06510816 |
| Longboard Pharmaceuticals | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) Asset: LP352 | Developmental and Epileptic Encephalopathy | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06719141 |
| Viatris Innovation GmbH | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Asset: Cenerimod | Lupus Erythematosus, Systemic | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05672576 |
| Takeda | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Asset: TAK-788 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT04129502 |
| AstraZeneca | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients Asset: Capivasertib | Breast Cancer | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 8mo ago
| NCT06635447 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Alectinib | Non-Small Cell Lung Cancer | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 8mo ago
| NCT03178552 |
| Sarepta Therapeutics, Inc. | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) Asset: Eteplirsen | Muscular Dystrophy, Duchenne | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · aging
Updated 9mo ago
| NCT03992430 |
| Jiangsu HengRui Medicine Co., Ltd. | Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative Asset: SHR6390 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | est. due Oct 2027 | Q4 2026 2026-10-31 (est.) | Estimated · stale
Updated 27mo ago
| NCT04842617 |
| Vertex Pharmaceuticals Incorporated | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Asset: VX-121/TEZ/D-IVA | Cystic Fibrosis | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT05444257 |
| AstraZeneca | A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | Asthma | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06471257 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes Asset: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR | Type 2 Diabetes | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT07026968 |
| Laekna Limited | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Asset: Afuresertib | Breast Cancer | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT04851613 |
| Beijing Continent Pharmaceutical C… | A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis Asset: Hydronidone Capsules | Chronic Hepatitis B With Hepatic Fibrosis | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT07343778 |
| Cali Pharmaceuticals LLC | Phase 3 Bunionectomy Study Asset: CPL-01 | Postoperative Pain +1 | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT07490496 |
| Kind Pharmaceuticals LLC | A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia Asset: AND017 capsules | Anemia Due to Chronic Kidney Disease | est. due Oct 2027 | Q4 2026 2026-10-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT07494409 |
| Merck Sharp & Dohme LLC | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Asset: Pembrolizumab | Carcinoma, Renal Cell | est. due Oct 2027 | Q4 2026 2026-10-29 (est.) | Estimated · stale
Updated 24mo ago
| NCT04736706 |
| Novartis Pharmaceuticals | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Asset: Ianalumab | Primary Immune Thrombocytopenia (ITP) | est. due Oct 2027 | Q4 2026 2026-10-29 (est.) | Estimated · aging
Updated 7mo ago
| NCT05653349 |
| Taiho Oncology, Inc. | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) Asset: TAS6417 | Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | est. due Oct 2027 | Q4 2026 2026-10-29 (est.) | Estimated · aging
Updated 8mo ago
| NCT05973773 |
| Merck Sharp & Dohme LLC | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) Asset: Belzutifan | Carcinoma, Renal Cell | est. due Oct 2027 | Q4 2026 2026-10-28 (est.) | Estimated · stale
Updated 15mo ago
| NCT05239728 |
| Akeso | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC Asset: Cadonilimab (AK104) | NSCLC (Non-small Cell Lung Cancer) | est. due Oct 2027 | Q4 2026 2026-10-28 (est.) | Estimated · stale
Updated 20mo ago
| NCT06617416 |
| CSL Behring | Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products Asset: Recombinant single-chain factor VIII (rVIII-SingleChain) | Congenital Hemophilia A | est. due Oct 2027 | Q4 2026 2026-10-26 (est.) | Estimated · aging
Updated 7mo ago
| NCT06738485 |
| Novartis Pharmaceuticals | Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events Asset: Inclisiran sodium 300 mg | Coronary Artery Disease | est. due Oct 2027 | Q4 2026 2026-10-26 (est.) | Estimated · aging
Updated 7mo ago
| NCT05360446 |
| Galderma R&D | A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Asset: Nemolizumab | Prurigo Nodularis | est. due Oct 2027 | Q4 2026 2026-10-26 (est.) | Estimated · aging
Updated 12mo ago
| NCT04204616 |
| Amgen | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Asset: Dazodalibep | Sjögren's Syndrome (SS) | est. due Oct 2027 | Q4 2026 2026-10-22 (est.) | Estimated · aging
Updated 10mo ago
| NCT06245408 |
| Otsuka Pharmaceutical Development … | A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia Asset: SEP-363856 | Schizophrenia | est. due Oct 2027 | Q4 2026 2026-10-20 (est.) | Estimated · aging
Updated 7mo ago
| NCT06894212 |
| Biogen | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Asset: Litifilimab | Subacute Cutaneous Lupus Erythematosus +1 | est. due Oct 2027 | Q4 2026 2026-10-20 (est.) | Estimated · aging
Updated 7mo ago
| NCT05531565 |
| LEO Pharma | A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis Asset: Tralokinumab + TCS | Atopic Dermatitis | est. due Oct 2027 | Q4 2026 2026-10-20 (est.) | Estimated · aging
Updated 8mo ago
| NCT06311682 |
| Incyte Corporation | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Asset: Povorcitinib | Prurigo Nodularis | est. due Oct 2027 | Q4 2026 2026-10-19 (est.) | Estimated · aging
Updated 7mo ago
| NCT06516952 |
| Incyte Corporation | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Asset: Povorcitinib | Prurigo Nodularis | est. due Oct 2027 | Q4 2026 2026-10-19 (est.) | Estimated · aging
Updated 7mo ago
| NCT06516965 |
| Bristol-Myers Squibb | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) Asset: Deucravacitinib | Systemic Lupus Erythematosus | est. due Oct 2027 | Q4 2026 2026-10-19 (est.) | Estimated · aging
Updated 11mo ago
| NCT05617677 |
| Bristol-Myers Squibb | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus Asset: Deucravacitinib | Systemic Lupus Erythematosus | est. due Oct 2027 | Q4 2026 2026-10-19 (est.) | Estimated · aging
Updated 11mo ago
| NCT05620407 |
| Han Xu, M.D., Ph.D., FAPCR, Medica… | Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers | Type 2 Diabetes | est. due Oct 2027 | Q4 2026 2026-10-18 (est.) | Estimated · stale
Updated 16mo ago
| NCT07033585 |
| Birch BioMed Inc | Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients Asset: IP1 control cream (Vehicle base) | Burn Scar +1 | est. due Oct 2027 | Q4 2026 2026-10-15 (est.) | Estimated · aging
Updated 12mo ago
| NCT06807021 |
| Suzhou Alphamab Co., Ltd. | Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors Asset: KN057 | Hemophilia A Without Inhibitor +1 | est. due Oct 2027 | Q4 2026 2026-10-15 (est.) | Estimated · stale
Updated 14mo ago
| NCT06569108 |
| Sandoz | Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis Asset: CYB704 | Relapsing Multiple Sclerosis | est. due Oct 2027 | Q4 2026 2026-10-14 (est.) | Estimated · aging
Updated 8mo ago
| NCT06847724 |
| Shanghai JMT-Bio Inc. | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Asset: JSKN003 | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | est. due Oct 2027 | Q4 2026 2026-10-13 (est.) | Estimated · stale
Updated 20mo ago
| NCT06846437 |
| Janssen Research & Development, LLC | A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC Asset: Apalutamide | Metastatic Castrate-sensitive Prostate Cancer | est. due Oct 2027 | Q4 2026 2026-10-12 (est.) | Estimated · aging
Updated 8mo ago
| NCT05884398 |
| Biocodex | Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome Asset: Saccharomyces Boulardii 250 MG | IBS (Irritable Bowel Syndrome) +2 | est. due Oct 2027 | Q4 2026 2026-10-11 (est.) | Estimated · aging
Updated 12mo ago
| NCT07168434 |
| Hangzhou Zhongmei Huadong Pharmace… | A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects Asset: MC2-01 cream | Plaque Psoriasis | est. due Oct 2027 | Q4 2026 2026-10-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT07357831 |
| Hangzhou Zhongmei Huadong Pharmace… | Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus Asset: HDM1002 200 mg | Type 2 Diabetes | est. due Oct 2027 | Q4 2026 2026-10-10 (est.) | Estimated · stale
Updated 14mo ago
| NCT07193459 |
| Incyte Corporation | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) Asset: Ruxolitinib Cream | Hidradenitis Suppurativa | est. due Oct 2027 | Q4 2026 2026-10-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06959225 |
| Incyte Corporation | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) Asset: Ruxolitinib Cream | Hidradenitis Suppurativa | est. due Oct 2027 | Q4 2026 2026-10-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06958211 |
| Pfizer | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine Asset: Rimegepant | Migraine | est. due Oct 2027 | Q4 2026 2026-10-08 (est.) | Estimated · aging
Updated 7mo ago
| NCT06616194 |
| CSPC ZhongQi Pharmaceutical Techno… | A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) | Methylmalonic Acidemia (MMA) | est. due Oct 2027 | Q4 2026 2026-10-08 (est.) | Estimated · stale
Updated 14mo ago
| NCT07163364 |
| Regeneron Pharmaceuticals | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Asset: Dupilumab | Atopic Dermatitis | est. due Oct 2027 | Q4 2026 2026-10-07 (est.) | Estimated · stale
Updated 17mo ago
| NCT02612454 |
| Bristol-Myers Squibb | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Asset: BMS-986278 | Idiopathic Pulmonary Fibrosis | est. due Oct 2027 | Q4 2026 2026-10-06 (est.) | Estimated · aging
Updated 8mo ago
| NCT06003426 |
| Karuna Therapeutics, Inc., a Brist… | A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) Asset: KarXT | Psychosis Associated With Alzheimer's Disease | est. due Oct 2027 | Q4 2026 2026-10-05 (est.) | Estimated · aging
Updated 7mo ago
| NCT05511363 |
| Takeda | A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy Asset: TAK-861 | Narcolepsy Type 1 (NT1) +1 | est. due Oct 2027 | Q4 2026 2026-10-02 (est.) | Estimated · aging
Updated 8mo ago
| NCT07363720 |
| Novo Nordisk A/S | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Asset: Ziltivekimab | Heart Failure +1 | est. due Oct 2027 | Q4 2026 2026-10-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT06200207 |
| argenx | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Asset: efgartigimod PH20 SC | Primary Immune Thrombocytopenia | est. due Oct 2027 | Q4 2026 2026-10-01 (est.) | Estimated · aging
Updated 10mo ago
| NCT04812925 |
| Beijing Dongfang Biotech Co., Ltd. | A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin Asset: Exendin-4 Fc fusion protein injection(1.2mg） | Type2 Diabetes Mellitus | est. due Oct 2027 | Q4 2026 2026-10-01 (est.) | Estimated · stale
Updated 14mo ago
| NCT06257966 |
| EyePoint Pharmaceuticals, Inc. | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 Asset: EYP-1901 | Wet Age Related Macular Degeneration +1 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT06683742 |
| Senseye, Inc. | REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool | PTSD - Post Traumatic Stress Disorder | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT07280065 |
| UroGen Pharma Ltd. | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer Asset: UGN-104 | Upper Urinary Tract Urothelial Carcinoma +1 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT06774131 |
| Debiopharm International SA | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) Asset: Debio 4326 | Central Precocious Puberty | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT06129539 |
| Actinogen Medical | Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Asset: Xanamem | Dementia Moderate +2 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT06125951 |
| Privo Technologies | A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers Asset: PRV211 (Intraoperative Cisplatin System) | Oral Squamous Cell Carcinoma | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT05893888 |
| AbbVie | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Asset: Aflibercept (EYLEA®) | AMD +5 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT05407636 |
| Organon and Co | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects Asset: tapinarof cream, 1% | Plaque Psoriasis | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT05172726 |
| Merz North America, Inc. | A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States Asset: NT 201 | Neuromuscular Agents +9 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT07122193 |
| Novadip Biosciences | A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia. Asset: NVD003 | Congenital Pseudarthrosis of Tibia | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT07112443 |
| Mirum Pharmaceuticals, Inc. | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Asset: Maralixibat | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 7mo ago
| NCT06553768 |
| Celldex Therapeutics | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) Asset: barzolvolimab | Chronic Spontaneous Urticaria | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 8mo ago
| NCT06455202 |
| Celldex Therapeutics | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Asset: barzolvolimab | Chronic Spontaneous Urticaria | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 8mo ago
| NCT06445023 |
| Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Asset: XEN1101 | Focal Onset Seizures | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 8mo ago
| NCT05716100 |
| Tenax Therapeutics, Inc. | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF Asset: TNX-103 | Pulmonary Hypertension | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 9mo ago
| NCT05983250 |
| Loxo Oncology, Inc. | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Asset: Pirtobrutinib | Chronic Lymphocytic Leukemia +1 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 9mo ago
| NCT04965493 |
| Mesoblast, Ltd. | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain Asset: Rexlemestrocel-L + HA mixture | Degenerative Disc Disease | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT06325566 |
| Akeso | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer Asset: AK112, Gemcitabine, Cisplatin | Biliary Tract Cancer | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT06591520 |
| Pharmazz, Inc. | A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent Asset: Normal Saline | Hypovolemic Shock | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT05251181 |
| Eli Lilly and Company | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Asset: Retatrutide | Type 2 Diabetes | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 11mo ago
| NCT06297603 |
| AFT Pharmaceuticals, Ltd. | A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain | Acute Pain | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 12mo ago
| NCT07225634 |
| AFT Pharmaceuticals, Ltd. | A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery Asset: Combogesic® tablets | Post Operative Pain, Acute | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · aging
Updated 12mo ago
| NCT07225140 |
| Ebima Clifford Okundaye | Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression Asset: QRX-3 | Chronic Kidney Diseases +2 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 14mo ago
| NCT06866236 |
| Zhejiang Sunshine Mandi Pharmaceut… | Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris Asset: Clascoterone | Acne Vulgaris | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 16mo ago
| NCT06403501 |
| GIE Medical | Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus | Esophageal Stricture | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 17mo ago
| NCT05561114 |
| Inmunotek S.L. | Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Asset: 10,000 MG01 +10,000 T521 | Rhinitis, Allergic +2 | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 18mo ago
| NCT04898283 |
| CSPC ZhongQi Pharmaceutical Techno… | Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors | HR+/HER2- Advanced/Metastatic Breast Cancer | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 19mo ago
| NCT06929325 |
| Humacyte, Inc. | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis Asset: Acellular Tissue Engineered Vessel (ATEV) | End Stage Renal Disease (ESRD) | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 20mo ago
| NCT05908084 |
| Chia Tai Tianqing Pharmaceutical G… | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure Asset: D-1553 Tablet | Non Small Cell Lung Cancer | est. due Oct 2027 | Q4 2026 2026-10 (est.) | Estimated · stale
Updated 31mo ago
| NCT06300177 |
| Q3 2026 · 95 | ||||||
| argenx | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis Asset: Efgartigimod PH20 SC | Generalized Myasthenia Gravis | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 11mo ago
| NCT06392386 |
| GlaxoSmithKline | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study Asset: RSVPreF3 OA vaccine | Respiratory Syncytial Virus Infections | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06534892 |
| Pfizer | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Asset: Avelumab | Advanced Malignancies +4 | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT05059522 |
| AstraZeneca | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Asset: Dato-DXd | Metastatic Non-small Cell Lung Cancer | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT06417814 |
| Glycomine, Inc. | A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG Asset: GLM101 (Part A, Double-blind) | Phosphomannomutase 2 Deficiency +1 | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT06892288 |
| GlaxoSmithKline | Linerixibat Long-term Safety, and Tolerability Study Asset: Linerixibat | Cholestasis | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT04167358 |
| Sinovac Biotech Co., Ltd | Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine Asset: Sinovac rabies vaccine | Rabies (Healthy Volunteers) | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT07416110 |
| Biogen | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Asset: Litifilimab | Lupus Erythematosus, Systemic | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT04895241 |
| UpTru Inc. | Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED) Asset: Fluorescein | Substance Use Disorder (SUD) | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT07356349 |
| Chongqing Claruvis Pharmaceutical … | A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults Asset: Recombinant Botulinum Toxin Type A for injection (YY001) | Upper Limb Spasticity | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 10mo ago
| NCT06783114 |
| Innovent Biopharmaceutical Technol… | A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis Asset: IBI112 | Psoriasis | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 11mo ago
| NCT07265284 |
| Beijing Continent Pharmaceutical C… | Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis Asset: Pirfenidone Capsules | Pneumoconiosis | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 12mo ago
| NCT05288179 |
| Beijing Pearl Biotechnology Limite… | A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) Asset: PLB1001 | Non-small Cell Lung Cancer | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 16mo ago
| NCT05989542 |
| Innovent Biologics (Suzhou) Co. Ltd. | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer Asset: Pemetrexed | Non-Small Cell Lung Cancer | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 17mo ago
| NCT05116462 |
| Fujian Shengdi Pharmaceutical Co.,… | A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes Asset: HRS9531 Injection | Type 2 Diabetes | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 17mo ago
| NCT06649344 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder Asset: Dextromethorphan and Bupropion Sustained-Release Tablets | Major Depressive Disorder (MDD) | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 18mo ago
| NCT06958692 |
| Allist Pharmaceuticals, Inc. | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation Asset: JAB-21822 | Advanced Non-squamous Non-small-cell Lung Cancer +1 | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 19mo ago
| NCT06416410 |
| Shanghai JMT-Bio Inc. | A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations Asset: JMT101 | Locally Advanced or Metastatic Non-squamous NSCLC +2 | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 23mo ago
| NCT06735391 |
| Hansoh BioMedical R&D Company | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer Asset: HS-20093 | Small Cell Lung Cancer | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 25mo ago
| NCT06498479 |
| SyneuRx International (Taiwan) Corp | An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults Asset: NaBen® | Refractory Schizophrenia | est. due Sep 2027 | Q3 2026 2026-09-30 (est.) | Estimated · stale
Updated 62mo ago
| NCT03094429 |
| GlaxoSmithKline | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Asset: Depemokimab | Eosinophilic Granulomatosis With Polyangiitis | est. due Sep 2027 | Q3 2026 2026-09-29 (est.) | Estimated · aging
Updated 12mo ago
| NCT05263934 |
| Ocugen | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease Asset: OCU410ST | Stargardt Disease | est. due Sep 2027 | Q3 2026 2026-09-28 (est.) | Estimated · aging
Updated 7mo ago
| NCT05956626 |
| Biogen | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Asset: Litifilimab | Lupus Erythematosus, Systemic | est. due Sep 2027 | Q3 2026 2026-09-27 (est.) | Estimated · aging
Updated 9mo ago
| NCT04961567 |
| Karuna Therapeutics, Inc., a Brist… | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) Asset: KarXT | Alzheimer Disease | est. due Sep 2027 | Q3 2026 2026-09-21 (est.) | Estimated · aging
Updated 7mo ago
| NCT06585787 |
| Cardiol Therapeutics Inc. | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) Asset: CardiolRx | Recurrent Pericarditis | est. due Sep 2027 | Q3 2026 2026-09-21 (est.) | Estimated · aging
Updated 8mo ago
| NCT06708299 |
| Hangzhou Zhongmei Huadong Pharmace… | Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes Asset: HDM1005 1 | Obesity & Overweight | est. due Sep 2027 | Q3 2026 2026-09-20 (est.) | Estimated · aging
Updated 11mo ago
| NCT07279194 |
| Han Xu, M.D., Ph.D., FAPCR, Medica… | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Asset: Topotecan - usual | SCLC | est. due Sep 2027 | Q3 2026 2026-09-18 (est.) | Estimated · stale
Updated 14mo ago
| NCT07145333 |
| Vertex Pharmaceuticals Incorporated | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant Asset: Biological/Vaccine | Type 1 Diabetes +1 | est. due Sep 2027 | Q3 2026 2026-09-17 (est.) | Estimated · aging
Updated 8mo ago
| NCT06832410 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Asset: Pembrolizumab | Endometrial Neoplasms | est. due Sep 2027 | Q3 2026 2026-09-15 (est.) | Estimated · stale
Updated 17mo ago
| NCT04634877 |
| Priovant Therapeutics, Inc. | A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Asset: Brepocitinib PO QD | Uveitis, Posterior +2 | est. due Sep 2027 | Q3 2026 2026-09-11 (est.) | Estimated · aging
Updated 10mo ago
| NCT06431373 |
| Applied Biology, Inc. | Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Asset: DA-007 | Chemotherapy Induced Alopecia +1 | est. due Sep 2027 | Q3 2026 2026-09-11 (est.) | Estimated · stale
Updated 18mo ago
| NCT06762548 |
| Galaxy Therapeutics INC | SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial | Intracranial Aneurysm | est. due Sep 2027 | Q3 2026 2026-09-10 (est.) | Estimated · aging
Updated 10mo ago
| NCT05831202 |
| GlaxoSmithKline | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age Asset: Candidate varicella vaccine | Chickenpox | est. due Sep 2027 | Q3 2026 2026-09-10 (est.) | Estimated · aging
Updated 11mo ago
| NCT06855160 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia Asset: IBI306 | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | est. due Sep 2027 | Q3 2026 2026-09-06 (est.) | Estimated · aging
Updated 7mo ago
| NCT07473960 |
| H. Lundbeck A/S | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine Asset: Eptinezumab | Chronic Migraine in Children | est. due Sep 2027 | Q3 2026 2026-09-05 (est.) | Estimated · aging
Updated 8mo ago
| NCT04965675 |
| UCB BIOSCIENCES, Inc. | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome Asset: fenfluramine | Dravet Syndrome | est. due Sep 2027 | Q3 2026 2026-09-03 (est.) | Estimated · aging
Updated 7mo ago
| NCT06118255 |
| Boehringer Ingelheim | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Asset: zongertinib | Lung Cancer, Non-squamous, Non-small Cell | est. due Sep 2027 | Q3 2026 2026-09-02 (est.) | Estimated · aging
Updated 7mo ago
| NCT06151574 |
| Newron Pharmaceuticals SPA | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia Asset: Evenamide 15 mg bid | Treatment-resistant Schizophrenia | est. due Sep 2027 | Q3 2026 2026-09-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT07184619 |
| Incyte Corporation | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Asset: Tafasitamab | Diffuse Large B-cell Lymphoma | est. due Sep 2027 | Q3 2026 2026-09-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT04824092 |
| Daewoong Pharmaceutical Co. LTD. | Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients Asset: DWP16001 Placebo | Type 2 Diabetic Nephropathy | est. due Sep 2027 | Q3 2026 2026-09-01 (est.) | Estimated · stale
Updated 26mo ago
| NCT06606093 |
| AbbVie | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Asset: Adalimumab | Juvenile Psoriatic Arthritis | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT06100744 |
| Disc Medicine, Inc | Study of Bitopertin in Participants With EPP or XLP (APOLLO) Asset: Placebo | Erythropoietic Protoporphyria (EPP) +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06910358 |
| Clarity Pharmaceuticals Ltd | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy Asset: 64Cu-SAR-bisPSMA | Prostate Cancer +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06056830 |
| Alkermes, Inc. | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder Asset: OLZ/SAM | Schizophrenia +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT05303064 |
| TWi Biotechnology, Inc. | An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) Asset: AC-203 | Generalized Epidermolysis Bullosa Simplex | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06073132 |
| vTv Therapeutics | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Asset: Cadisegliatin 800 mg QD | Diabetes Mellitus, Type 1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06334133 |
| Jiangsu BioJeTay Biotechnology Co.… | Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients Asset: STSP-0601 for Injection | Hemophilia | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06922045 |
| Eli Lilly and Company | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) Asset: LY3650150 | Perennial Allergic Rhinitis (PAR) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06339008 |
| Curium US LLC | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Asset: Copper Cu 64 PSMA I&T | Prostate Cancer +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 7mo ago
| NCT06235151 |
| argenx | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy Asset: Empasiprubart | Multifocal Motor Neuropathy (MMN) +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 8mo ago
| NCT06742190 |
| Cook MyoSite | Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence Asset: AMDC-USR (iltamiocel) | Stress Urinary Incontinence | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 8mo ago
| NCT03104517 |
| Eli Lilly and Company | A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Asset: Baricitinib | Systemic Juvenile Idiopathic Arthritis | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT04088396 |
| ScandiBio Therapeutics AB | Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease Asset: Combined metabolic activators | Alzheimer Disease | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 9mo ago
| NCT07062198 |
| Pharmazz, Inc. | Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke Asset: Drug: Normal Saline | Acute Ischemic Stroke +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 10mo ago
| NCT05691244 |
| Atea Pharmaceuticals, Inc. | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Asset: Bemnifosbuvir-Ruzasvir (BEM/RZR) | HEPATITIS C VIRUS CHRONIC INFECTION | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · aging
Updated 11mo ago
| NCT06868264 |
| Shandong Suncadia Medicine Co., Ltd. | A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy Asset: HRS-1893 Tablets | Obstructive Hypertrophic Cardiomyopathy | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 15mo ago
| NCT07021976 |
| EyeBiotech Ltd. | A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Asset: Ranibizumab | Diabetic Macular Edema (DME) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 15mo ago
| NCT06571045 |
| Qilu Pharmaceutical Co., Ltd. | GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer Asset: GM1 | Chemotherapy-induced Peripheral Neuropathy (CIPN) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 15mo ago
| NCT06994507 |
| Intra-Cellular Therapies, Inc. | Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Asset: Lumateperone | Major Depressive Disorder | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 16mo ago
| NCT05850689 |
| Supernus Pharmaceuticals, Inc. | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) Asset: SPN-812 | Attention-Deficit/Hyperactivity Disorder | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 17mo ago
| NCT02736656 |
| Mabwell (Shanghai) Bioscience Co.,… | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer Asset: 9MW2821 | Advanced Urothelial Carcinoma | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 19mo ago
| NCT06196736 |
| Rophibio, Inc. | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration Asset: RBS-001 Solution for intravitreal injection | Neovascular Age-related Macular Degeneration (nAMD) | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 19mo ago
| NCT06470373 |
| Bio-Thera Solutions | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Asset: Recombinant humanized anti-PD-1 monoclonal antibody injection | Cervical Cancer | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 21mo ago
| NCT06123884 |
| Alfasigma S.p.A. | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Asset: Filgotinib | Ulcerative Colitis | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 21mo ago
| NCT02914535 |
| Chia Tai Tianqing Pharmaceutical G… | A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients Asset: TQB2450+Anlotinib | Small Cell Lung Cancer Limited Stage | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 28mo ago
| NCT06469879 |
| Salutaris Medical Devices, Inc. | Adjunct Episcleral Brachytherapy for PCV Asset: Aflibercept Injection | Age-Related Macular Degeneration +1 | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 38mo ago
| NCT05251636 |
| CSPC Zhongnuo Pharmaceutical (Shij… | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment Asset: Mitoxantrone hydrochloride liposome injection | Recurrent Metastatic Nasopharyngeal Carcinoma | est. due Sep 2027 | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 45mo ago
| NCT05717764 |
| Daiichi Sankyo | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Asset: Trastuzumab deruxtecan | Gastric Cancer, Adenocarcinoma +1 | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 10mo ago
| NCT04704934 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Asset: Sefaxersen (RO7434656) | Primary IgA Nephropathy | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05797610 |
| Bayer | A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: BAY3723113 | Obstructive Hypertrophic Cardiomyopathy | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT07023341 |
| Pfizer | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. Asset: RSVpreF | Respiratory Syncytial Virus (RSV) | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT07543380 |
| AMAG Pharmaceuticals, Inc. | A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Asset: Ferumoxytol | Chronic Kidney Disease; Iron Deficiency Anemia | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT03619850 |
| Hansoh BioMedical R&D Company | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure Asset: HS-20093 | Osteosarcoma | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT06935409 |
| Anthos Therapeutics, Inc. | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Asset: Abelacimab | Atrial Fibrillation (AF) | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 7mo ago
| NCT05712200 |
| Sichuan Jishengtang Pharmaceutical… | Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney) Asset: Wujia Yizhi granules | Alzheimer's Dementia | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 10mo ago
| NCT06534723 |
| Kringle Pharma, Inc. | Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar Asset: KP-100LI | Vocal Fold Scar | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · aging
Updated 11mo ago
| NCT05627648 |
| Daewon Pharmaceutical Co., Ltd. | Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma Asset: Experimental | Perennial Allergic Rhinitis Accompanied by Asthma | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · stale
Updated 14mo ago
| NCT07168473 |
| Galderma R&D | Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Asset: Nemolizumab | Moderate-to-Severe Atopic Dermatitis | est. due Aug 2027 | Q3 2026 2026-08-31 (est.) | Estimated · stale
Updated 24mo ago
| NCT03989206 |
| Pfizer | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Asset: Elranatamab | Multiple Myeloma | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06152575 |
| Takeda | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults Asset: Tetravalent Dengue Vaccine (TDV) | Dengue Fever | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · aging
Updated 9mo ago
| NCT07047521 |
| Keymed Biosciences Co.Ltd | Study of CM310 in Adolescent Subjects With Atopic Dermatis Asset: CM310 | Atopic Dermatitis | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 13mo ago
| NCT06495229 |
| Hutchmed | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Asset: Savolitinib | Non-small Cell Lung Cancer | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT05009836 |
| Beletalent (Zhuhai) Pharmaceutical… | Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy Asset: TNTL | Non-Proliferative Diabetic Retinopathy | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 15mo ago
| NCT06817265 |
| Il-Yang Pharm. Co., Ltd. | Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer Asset: Ilaprazole | Peptic Ulcer | est. due Aug 2027 | Q3 2026 2026-08-30 (est.) | Estimated · stale
Updated 17mo ago
| NCT06284876 |
| Panbela Therapeutics, Inc. | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Asset: SBP-101 | Pancreatic Cancer Metastatic +2 | est. due Aug 2027 | Q3 2026 2026-08-29 (est.) | Estimated · stale
Updated 24mo ago
| NCT05254171 |
| UCB Biopharma SRL | A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Asset: Brivaracetam | Childhood Absence Epilepsy +1 | est. due Aug 2027 | Q3 2026 2026-08-24 (est.) | Estimated · aging
Updated 8mo ago
| NCT04666610 |
| AstraZeneca | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease Asset: AZD9833 | ER-Positive HER2-Negative Breast Cancer | est. due Aug 2027 | Q3 2026 2026-08-24 (est.) | Estimated · stale
Updated 13mo ago
| NCT04711252 |
| Longboard Pharmaceuticals | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Asset: LP352 | Dravet Syndrome | est. due Aug 2027 | Q3 2026 2026-08-21 (est.) | Estimated · aging
Updated 7mo ago
| NCT06660394 |
| EMD Serono Research & Development … | Avelumab Program Rollover Study Asset: Avelumab | Solid Tumors | est. due Aug 2027 | Q3 2026 2026-08-21 (est.) | Estimated · aging
Updated 7mo ago
| NCT03815643 |
| ViiV Healthcare | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 Asset: CAB LA + RPV LA | HIV Infections | est. due Aug 2027 | Q3 2026 2026-08-19 (est.) | Estimated · aging
Updated 7mo ago
| NCT06694805 |
| Amgen | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Asset: Dazodalibep | Sjogren's Syndrome | est. due Aug 2027 | Q3 2026 2026-08-19 (est.) | Estimated · aging
Updated 10mo ago
| NCT06104124 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Asset: pembrolizumab/vibostolimab | Carcinoma, Non-Small-Cell Lung | est. due Aug 2027 | Q3 2026 2026-08-19 (est.) | Estimated · stale
Updated 15mo ago
| NCT05298423 |
| Shanghai Fudan-Zhangjiang Bio-Phar… | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Asset: FDA018-ADC | Triple Negative Breast Cancer | est. due Aug 2027 | Q3 2026 2026-08-18 (est.) | Estimated · aging
Updated 10mo ago
| NCT06519370 |
| Genzyme, a Sanofi Company | Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Asset: Fitusiran | Hemophilia | est. due Aug 2027 | Q3 2026 2026-08-15 (est.) | Estimated · stale
Updated 15mo ago
| NCT03974113 |
| AstraZeneca | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. Asset: Nexium 20mg | Erosive Esophagitis | est. due Aug 2027 | Q3 2026 2026-08-14 (est.) | Estimated · aging
Updated 7mo ago
| NCT05267613 |
Recently read out & awaiting topline
· 162Phase 3 trials whose primary completion is CONFIRMED by CT.gov (last 12 months) — results posted, or completed and awaiting topline. Most recent first.
All 162 completed and awaiting topline — CT.gov results typically post within 12 months of completion · most recent confirmed: Inventera Inc. (2026-04-14)
| Sponsor | Trial / Asset | Indication | Results | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Q2 2026 · 7 | ||||||
| Inventera Inc. | Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases Asset: NEMO-103 Injection | Rotator Cuff Tear +7 | Due Apr 2027 | Q2 2026 2026-04-14 | Completed · awaiting
Updated 7mo ago
| NCT07057037 |
| UCB Biopharma SRL | A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis Asset: Certolizumab pegol | Moderate Chronic Plaque Psoriasis +2 | Due Apr 2027 | Q2 2026 2026-04-09 | Completed · awaiting
Updated 7mo ago
| NCT04123795 |
| Alcon Research | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Ocular Hypertension +1 | Due Apr 2027 | Q2 2026 2026-04-06 | Completed · awaiting
Updated 7mo ago
| NCT07082816 |
| Arog Pharmaceuticals, Inc. | Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Asset: Crenolanib | Newly Diagnosed FLT3 Mutated AML | Due Apr 2027 | Q2 2026 2026-04-06 | Completed · awaiting
Updated 7mo ago
| NCT03258931 |
| Ondine Biomedical Inc. | Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections | Surgical Site Infections +3 | Due Apr 2027 | Q2 2026 2026-04-03 | Completed · awaiting
Updated 7mo ago
| NCT06702878 |
| Arog Pharmaceuticals, Inc. | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Asset: Crenolanib | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Due Apr 2027 | Q2 2026 2026-04-03 | Completed · awaiting
Updated 7mo ago
| NCT03250338 |
| Insmed Incorporated | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Pulmonary Hypertension +1 | Due Apr 2027 | Q2 2026 2026-04-01 | Completed · awaiting
Updated 7mo ago
| NCT05649722 |
| Q1 2026 · 82 | ||||||
| Novartis Pharmaceuticals | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Asset: Fingolimod | Multiple Sclerosis (MS) | Due Mar 2027 | Q1 2026 2026-03-25 | Completed · awaiting
Updated 7mo ago
| NCT04926818 |
| Novartis Pharmaceuticals | Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD Asset: Pelacarsen | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | Due Mar 2027 | Q1 2026 2026-03-25 | Completed · awaiting
Updated 7mo ago
| NCT06267560 |
| Astellas Pharma Inc | A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause Asset: Fezolinetant | Hot Flashes | Due Mar 2027 | Q1 2026 2026-03-19 | Completed · awaiting
Updated 7mo ago
| NCT06206421 |
| Incyte Corporation | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) Asset: Povorcitinib | NonSegmental Vitiligo | Due Mar 2027 | Q1 2026 2026-03-17 | Completed · awaiting
Updated 7mo ago
| NCT06113471 |
| Eli Lilly and Company | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron | Type 2 Diabetes +5 | Due Mar 2027 | Q1 2026 2026-03-16 | Completed · awaiting
Updated 7mo ago
| NCT05803421 |
| Sandoz | A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Asset: GME751 | Metastatic NSCLC | Due Mar 2027 | Q1 2026 2026-03-16 | Completed · awaiting
Updated 7mo ago
| NCT06159790 |
| Regeneron Pharmaceuticals | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Asset: Fianlimab | Melanoma | Due Mar 2027 | Q1 2026 2026-03-12 | Completed · awaiting
Updated 7mo ago
| NCT05352672 |
| Merck Sharp & Dohme LLC | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Lung Cancer +1 | Due Mar 2027 | Q1 2026 2026-03-12 | Completed · awaiting
Updated 7mo ago
| NCT06698042 |
| argenx | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Asset: efgartigimod | Primary Immune Thrombocytopenia | Due Mar 2027 | Q1 2026 2026-03-11 | Completed · awaiting
Updated 8mo ago
| NCT04225156 |
| Amgen | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer Asset: Romiplostim | Chemotherapy-induced Thrombocytopenia | Due Mar 2027 | Q1 2026 2026-03-10 | Completed · awaiting
Updated 7mo ago
| NCT03937154 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Placebo | Chronic Obstructive Pulmonary Disease (COPD) | Due Mar 2027 | Q1 2026 2026-03-06 | Completed · awaiting
Updated 8mo ago
| NCT06040086 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes | Due Mar 2027 | Q1 2026 2026-03-04 | Completed · awaiting
Updated 7mo ago
| NCT06221969 |
| Eli Lilly and Company | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Asset: Mirikizumab | Ulcerative Colitis | Due Mar 2027 | Q1 2026 2026-03-04 | Completed · awaiting
Updated 7mo ago
| NCT03519945 |
| Sanofi | Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Asset: avalglucosidase alfa | Glycogen Storage Disease Type II | Due Mar 2027 | Q1 2026 2026-03-02 | Completed · awaiting
Updated 7mo ago
| NCT04910776 |
| Sarfez Pharmaceuticals, Inc. | Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone | Bioavailability Heathy Volunteers | Due Feb 2027 | Q1 2026 2026-02-28 | Completed · awaiting
Updated 8mo ago
| NCT07046975 |
| AstraZeneca | Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). | Chronic Obstructive Pulmonary Disease (COPD) | Due Feb 2027 | Q1 2026 2026-02-26 | Completed · awaiting
Updated 8mo ago
| NCT05742802 |
| Incyte Corporation | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) Asset: Povorcitinib | NonSegmental Vitiligo | Due Feb 2027 | Q1 2026 2026-02-24 | Completed · awaiting
Updated 8mo ago
| NCT06113445 |
| Novartis Pharmaceuticals | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Asset: Secukinumab 300 mg, s.c. | Giant Cell Arteritis | Due Feb 2027 | Q1 2026 2026-02-24 | Completed · awaiting
Updated 9mo ago
| NCT05380453 |
| AstraZeneca | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC Asset: Tremelimumab | Hepatocellular Carcinoma | Due Feb 2027 | Q1 2026 2026-02-23 | Completed · awaiting
Updated 7mo ago
| NCT05301842 |
| Karyopharm Therapeutics Inc | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Asset: Selinexor | Myelofibrosis | Due Feb 2027 | Q1 2026 2026-02-20 | Completed · awaiting
Updated 7mo ago
| NCT04562389 |
| Novartis Pharmaceuticals | A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia Asset: Ianalumab | Warm Autoimmune Hemolytic Anemia (wAIHA) | Due Feb 2027 | Q1 2026 2026-02-20 | Completed · awaiting
Updated 8mo ago
| NCT05648968 |
| Pfizer | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Asset: talazoparib plus enzalutamide | Prostate Cancer | Due Feb 2027 | Q1 2026 2026-02-18 | Completed · awaiting
Updated 7mo ago
| NCT04821622 |
| Celltrion | A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis Asset: CT-P55 | Plaque Psoriasis | Due Feb 2027 | Q1 2026 2026-02-18 | Completed · awaiting
Updated 9mo ago
| NCT06630559 |
| Bristol-Myers Squibb | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Asset: Nivolumab | Urinary Bladder Neoplasms +1 | Due Feb 2027 | Q1 2026 2026-02-16 | Completed · awaiting
Updated 7mo ago
| NCT03661320 |
| RDC Clinical Pty Ltd | Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population Asset: Maolactin | Chronic Inflammation +3 | Due Feb 2027 | Q1 2026 2026-02-16 | Completed · awaiting
Updated 8mo ago
| NCT06444763 |
| Astellas Pharma Global Development… | A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity Asset: mirabegron | Neurogenic Detrusor Overactivity | Due Feb 2027 | Q1 2026 2026-02-16 | Completed · awaiting
Updated 8mo ago
| NCT05621616 |
| Beijing Suncadia Pharmaceuticals C… | A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Asset: SHR-2004 injection | Prevention of Arterial and Venous Thrombosis | Due Feb 2027 | Q1 2026 2026-02-15 | Completed · awaiting
Updated 7mo ago
| NCT06825416 |
| Boston Scientific Corporation | MANDARIN (S6371) | Inoperable Hepatocellular Carcinoma | Due Feb 2027 | Q1 2026 2026-02-13 | Completed · awaiting
Updated 7mo ago
| NCT05016245 |
| Viridian Therapeutics, Inc. | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) Asset: VRDN-003 | Thyroid Eye Disease | Due Feb 2027 | Q1 2026 2026-02-12 | Completed · awaiting
Updated 7mo ago
| NCT06625411 |
| Taisho Pharmaceutical Indonesia | Counterpain PXM Versus Diclofenac Versus Piroxicam | Ankle Sprain +4 | Due Feb 2027 | Q1 2026 2026-02-12 | Completed · awaiting
Updated 8mo ago
| NCT07475663 |
| UCB Biopharma SRL | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Asset: Bimekizumab | Psoriatic Arthritis | Due Feb 2027 | Q1 2026 2026-02-06 | Completed · awaiting
Updated 7mo ago
| NCT06624228 |
| Janssen Research & Development, LLC | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome Asset: Milvexian | Acute Coronary Syndrome | Due Feb 2027 | Q1 2026 2026-02-06 | Completed · awaiting
Updated 7mo ago
| NCT05754957 |
| Forma Therapeutics, Inc. | A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Asset: Etavopivat Tablets Low dose | Sickle Cell Disease | Due Feb 2027 | Q1 2026 2026-02-06 | Completed · awaiting
Updated 7mo ago
| NCT04624659 |
| Daewoong Pharmaceutical Co. LTD. | A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension Asset: DWC202405 | Essential Hypertension | Due Feb 2027 | Q1 2026 2026-02-05 | Completed · awaiting
Updated 8mo ago
| NCT06671392 |
| Pfizer | A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo Asset: Ritlecitinib | Stable Nonsegmental Vitiligo +1 | Due Feb 2027 | Q1 2026 2026-02-05 | Completed · awaiting
Updated 9mo ago
| NCT05583526 |
| AbbVie | A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality | Skin Quality Deficit | Due Feb 2027 | Q1 2026 2026-02-05 | Completed · awaiting
Updated 9mo ago
| NCT06547125 |
| AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma | Open-Angle Glaucoma | Due Feb 2027 | Q1 2026 2026-02-04 | Completed · awaiting
Updated 9mo ago
| NCT05411198 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Due Feb 2027 | Q1 2026 2026-02-03 | Completed · awaiting
Updated 7mo ago
| NCT06235086 |
| Immunovant Sciences GmbH | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Asset: Batoclimab | Thyroid Eye Disease | Due Feb 2027 | Q1 2026 2026-02-03 | Completed · awaiting
Updated 7mo ago
| NCT05524571 |
| Merck Sharp & Dohme LLC | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Asset: Belzutifan | Carcinoma, Renal Cell | Due Feb 2027 | Q1 2026 2026-02-02 | Completed · awaiting
Updated 8mo ago
| NCT04586231 |
| United Therapeutics | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Asset: Placebo | Idiopathic Pulmonary Fibrosis +1 | Due Feb 2027 | Q1 2026 2026-02-02 | Completed · awaiting
Updated 7mo ago
| NCT04708782 |
| Tasly Pharmaceutical Group Co., Ltd | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Asset: pimavanserin tartrate | Parkinson's Disease Psychosis | Due Feb 2027 | Q1 2026 2026-02-01 | Completed · awaiting
Updated 9mo ago
| NCT06068465 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Asset: Giredestrant | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Due Jan 2027 | Q1 2026 2026-01-30 | Completed · awaiting
Updated 9mo ago
| NCT04546009 |
| Mundipharma Research Limited | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Asset: Rezafungin for Injection | Candidemia +9 | Due Jan 2027 | Q1 2026 2026-01-29 | Completed · awaiting
Updated 7mo ago
| NCT04368559 |
| Vertex Pharmaceuticals Incorporated | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older Asset: ELX/TEZ/IVA | Cystic Fibrosis | Due Jan 2027 | Q1 2026 2026-01-29 | Completed · awaiting
Updated 8mo ago
| NCT05153317 |
| Novartis Pharmaceuticals | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Asset: Ofatumumab approved dose | Relapsing Multiple Sclerosis (RMS) | Due Jan 2027 | Q1 2026 2026-01-28 | Completed · awaiting
Updated 7mo ago
| NCT06869785 |
| Colgate Palmolive | The Efficacy of a Battery Toothbrush in the Reduction of Established Plaque and Gingivitis Asset: Total Active Prevention Fresh Toothpaste + Colgate Total Active Prevention Battery Toothbrush | Plaque +1 | Due Jan 2027 | Q1 2026 2026-01-28 | Completed · awaiting
Updated 9mo ago
| NCT07224828 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Asset: Fenebrutinib | Relapsing Multiple Sclerosis | Due Jan 2027 | Q1 2026 2026-01-27 | Completed · awaiting
Updated 9mo ago
| NCT04586010 |
| Cassiopea SpA | A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss Asset: Clascoterone 5% solution | Alopecia, Androgenetic | Due Jan 2027 | Q1 2026 2026-01-26 | Completed · awaiting
Updated 8mo ago
| NCT05910450 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Due Jan 2027 | Q1 2026 2026-01-23 | Completed · awaiting
Updated 7mo ago
| NCT06258148 |
| Eli Lilly and Company | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Asset: Retatrutide | Diabetes Type 2 | Due Jan 2027 | Q1 2026 2026-01-22 | Completed · awaiting
Updated 8mo ago
| NCT06354660 |
| AstraZeneca | A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Asset: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate | Chronic Obstructive Pulmonary Disease | Due Jan 2027 | Q1 2026 2026-01-22 | Completed · awaiting
Updated 8mo ago
| NCT06067828 |
| Sun Pharmaceutical Industries Limi… | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. Asset: Tildrakizumab 100 mg | Moderate to Severe Genital Psoriasis | Due Jan 2027 | Q1 2026 2026-01-21 | Completed · awaiting
Updated 8mo ago
| NCT06611163 |
| Eli Lilly and Company | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Asset: Tirzepatide | Overweight +1 | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 8mo ago
| NCT06047548 |
| Takeda | A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases Asset: TAK-881 | Primary Immunodeficiency Diseases (PID) | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 9mo ago
| NCT05755035 |
| Sanofi | Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults Asset: Yellow fever vaccine (live) | Yellow Fever Immunization | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 9mo ago
| NCT07002060 |
| IBSA Institut Biochimique SA | Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer. Asset: Progesterone-IBSA Injectable Solution | Infertility | Due Jan 2027 | Q1 2026 2026-01-20 | Completed · awaiting
Updated 10mo ago
| NCT04549116 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Due Jan 2027 | Q1 2026 2026-01-19 | Completed · awaiting
Updated 7mo ago
| NCT05166889 |
| AstraZeneca | Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. Asset: Tozorakimab | Chronic Obstructive Pulmonary Disease (COPD) | Due Jan 2027 | Q1 2026 2026-01-19 | Completed · awaiting
Updated 7mo ago
| NCT05158387 |
| Nanjing Zenshine Pharmaceuticals | Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza Asset: ZX-7101A for oral suspension | Respiratory Viral Infection | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 7mo ago
| NCT07095257 |
| Lipocine Inc. | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD Asset: LPCN 1154A | Depression, Postpartum +5 | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 9mo ago
| NCT06979544 |
| Bristol-Myers Squibb | A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Asset: mavacamten | Hypertrophic Cardiomyopathy +2 | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 9mo ago
| NCT03723655 |
| Dizal Pharmaceuticals | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) Asset: sunvozertinib | Non-small Cell Lung Cancer | Due Jan 2027 | Q1 2026 2026-01-16 | Completed · awaiting
Updated 9mo ago
| NCT05668988 |
| Yuhan Corporation | Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis Asset: YHP2401 | Acute Bronchitis | Due Jan 2027 | Q1 2026 2026-01-15 | Completed · awaiting
Updated 9mo ago
| NCT07111468 |
| Immedica Pharma AB | Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia Asset: Chronocort | Congenital Adrenal Hyperplasia | Due Jan 2027 | Q1 2026 2026-01-15 | Completed · awaiting
Updated 9mo ago
| NCT05299554 |
| KalVista Pharmaceuticals, Ltd. | Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II Asset: KVD900 150 mg | Hereditary Angioedema | Due Jan 2027 | Q1 2026 2026-01-15 | Completed · awaiting
Updated 10mo ago
| NCT06467084 |
| Shanghai Hutchison Pharmaceuticals… | Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy Asset: Shenqi Sherong Pill | Cervical Spondylotic Myelopathy | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 7mo ago
| NCT06377072 |
| Palvella Therapeutics, Inc. | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations Asset: QTORIN 3.9% Rapamycin Anhydrous Gel | Microcystic Lymphatic Malformation | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 8mo ago
| NCT06239480 |
| Merck Sharp & Dohme LLC | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Asset: pembrolizumab | Hodgkin Lymphoma | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 9mo ago
| NCT02684292 |
| Amgen | A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease Asset: Teprotumumab | Thyroid Eye Disease | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 9mo ago
| NCT06248619 |
| Eli Lilly and Company | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Asset: Lebrikizumab | Atopic Dermatitis +1 | Due Jan 2027 | Q1 2026 2026-01-14 | Completed · awaiting
Updated 10mo ago
| NCT05559359 |
| Seagen, a wholly owned subsidiary … | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Asset: Brentuximab vedotin | Diffuse Large B-cell Lymphoma | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 7mo ago
| NCT04404283 |
| Janssen Research & Development, LLC | A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis Asset: Ustekinumab | Arthritis, Juvenile | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 7mo ago
| NCT05083182 |
| Pfizer | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Asset: Encorafenib | Melanoma | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 7mo ago
| NCT04657991 |
| Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Asset: XEN1101 | Focal Onset Seizures | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 8mo ago
| NCT05614063 |
| Eli Lilly and Company | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Asset: Selpercatinib | Carcinoma, Non-Small-Cell Lung | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 8mo ago
| NCT04819100 |
| Chiesi Farmaceutici S.p.A. | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Asset: Beclomethasone Dipropionate | COPD +1 | Due Jan 2027 | Q1 2026 2026-01-12 | Completed · awaiting
Updated 9mo ago
| NCT04320342 |
| RDC Clinical Pty Ltd | LC-Plasma for Preventing URTIs and Reducing Symptoms | Healthy Volunteer +1 | Due Jan 2027 | Q1 2026 2026-01-10 | Completed · awaiting
Updated 8mo ago
| NCT06827327 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab | Psoriasis +1 | Due Jan 2027 | Q1 2026 2026-01-08 | Completed · awaiting
Updated 10mo ago
| NCT06588283 |
| Alexion Pharmaceuticals, Inc. | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP Asset: ALXN1850 | Hypophosphatasia | Due Jan 2027 | Q1 2026 2026-01-06 | Completed · awaiting
Updated 9mo ago
| NCT06079359 |
| Chengdu Suncadia Medicine Co., Ltd. | Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment Asset: HRS-5965 capsule | Paroxysmal Nocturnal Hemoglobinuria | Due Jan 2027 | Q1 2026 2026-01-06 | Completed · awaiting
Updated 10mo ago
| NCT06715943 |
| Alexion Pharmaceuticals, Inc. | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Asset: Ravulizumab | Immunoglobulin A Nephropathy +1 | Due Jan 2027 | Q1 2026 2026-01-05 | Completed · awaiting
Updated 7mo ago
| NCT06291376 |
| Q4 2025 · 73 | ||||||
| United Therapeutics | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Asset: Ralinepag | PAH +10 | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 7mo ago
| NCT03626688 |
| Innovent Biologics (Suzhou) Co. Ltd. | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC Asset: IBI310 | Hepatocellular Carcinoma | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 8mo ago
| NCT04720716 |
| RDC Clinical Pty Ltd | Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults Asset: Grape Seed Extract | Circulatory; Change | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 8mo ago
| NCT06440252 |
| Bayer | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease Asset: Finerenone (BAY94-8862) | Non-diabetic Chronic Kidney Disease | Due Dec 2026 | Q4 2025 2025-12-31 | Completed · awaiting
Updated 9mo ago
| NCT05047263 |
| Hoffmann-La Roche | A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Asset: Atezolizumab | Non-Small Cell Lung Cancer | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 7mo ago
| NCT05047250 |
| Colgate Palmolive | Clinical Investigation of PerioGard (Test) Regimen Asset: PeriGuard regimen | Gingivitis | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 8mo ago
| NCT07210138 |
| Quoin Pharmaceuticals | Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome Asset: QRX003-2% Lotion | Netherton Syndrome | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 8mo ago
| NCT05521438 |
| Sarfez Pharmaceuticals, Inc. | A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects | Bioavailability Heathy Volunteers | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 8mo ago
| NCT07043634 |
| Sarfez Pharmaceuticals, Inc. | Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects Asset: 10 mg Torsemide tablet | Bioequivalence Study in Healthy Subjects +1 | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 8mo ago
| NCT07015671 |
| Mineralys Therapeutics Inc. | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension Asset: Lorundrostat | Hypertension | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 9mo ago
| NCT05968430 |
| Hoffmann-La Roche | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Asset: Atezolizumab | Non-Small Cell Lung Cancer | Due Dec 2026 | Q4 2025 2025-12-30 | Completed · awaiting
Updated 9mo ago
| NCT04294810 |
| Bayer | A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema Asset: 8 mg aflibercept (BAY 86-5321) (High Dose) | Diabetic Macular Edema | Due Dec 2026 | Q4 2025 2025-12-29 | Completed · awaiting
Updated 7mo ago
| NCT06422507 |
| Alexion Pharmaceuticals, Inc. | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG Asset: Eculizumab | Generalized Myasthenia Gravis (gMG) +1 | Due Dec 2026 | Q4 2025 2025-12-29 | Completed · awaiting
Updated 10mo ago
| NCT06764160 |
| Sanofi Pasteur, a Sanofi Company | Phase 3 Single Arm, Open Study on vYF in Adults Asset: Yellow fever vaccine (live) | Yellow Fever | Due Dec 2026 | Q4 2025 2025-12-25 | Completed · awaiting
Updated 9mo ago
| NCT07222059 |
| Haisco Pharmaceutical Group Co., L… | Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia Asset: HSK39297 tablets | Paroxysmal Nocturnal Haemoglobinuria (PNH) | Due Dec 2026 | Q4 2025 2025-12-23 | Completed · awaiting
Updated 9mo ago
| NCT07052838 |
| SynOx Therapeutics Limited | Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Asset: Emactuzumab | TGCT | Due Dec 2026 | Q4 2025 2025-12-23 | Completed · awaiting
Updated 9mo ago
| NCT05417789 |
| Amzell | A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms Asset: AMZ001 Diclofenac gel | Osteoarthritis of Knee +1 | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 10mo ago
| NCT06693648 |
| Hoffmann-La Roche | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Asset: Obinutuzumab | Primary Membranous Nephropathy | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 7mo ago
| NCT04629248 |
| Rhythm Pharmaceuticals, Inc. | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Asset: Setmelanotide | Obesity +1 | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 9mo ago
| NCT05093634 |
| Merck Sharp & Dohme LLC | V114 and Acute Otitis Media (V114-032/PNEU-ERA) Asset: V114 | Acute Otitis Media (AOM) | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 10mo ago
| NCT04193215 |
| Pfizer | Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Asset: Abrocitinib 100 mg | Dermatitis, Atopic | Due Dec 2026 | Q4 2025 2025-12-22 | Completed · awaiting
Updated 10mo ago
| NCT03422822 |
| Colgate Palmolive | Clinical Study to Evaluate the Tooth Whitening Efficacy of a New NextGen In-office Whitening System Asset: Beaming White | Health Adult Subjects | Due Dec 2026 | Q4 2025 2025-12-21 | Completed · awaiting
Updated 10mo ago
| NCT07225478 |
| Boston Scientific Corporation | A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort | In-Stent Restenosis | Due Dec 2026 | Q4 2025 2025-12-19 | Completed · awaiting
Updated 8mo ago
| NCT06492174 |
| QED Therapeutics, a BridgeBio comp… | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Asset: Infigratinib 0.25 mg/kg/day | Achondroplasia | Due Dec 2026 | Q4 2025 2025-12-18 | Completed · awaiting
Updated 8mo ago
| NCT06164951 |
| Quince Therapeutics S.p.A. | Evaluate the Neurological Effects of EryDex on Subjects With A-T | Ataxia Telangiectasia | Due Dec 2026 | Q4 2025 2025-12-17 | Completed · awaiting
Updated 10mo ago
| NCT06193200 |
| Sanofi | A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Asset: Venglustat (GZ402671) | Fabry Disease | Due Dec 2026 | Q4 2025 2025-12-17 | Completed · awaiting
Updated 9mo ago
| NCT05206773 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Obesity +1 | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 7mo ago
| NCT06066528 |
| Sanofi | Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 Asset: Eliglustat GZ385660 | Gaucher's Disease Type I +1 | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 10mo ago
| NCT03485677 |
| Boehringer Ingelheim | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Asset: Brigimadlin | Liposarcoma, Dedifferentiated | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 10mo ago
| NCT06058793 |
| Apellis Pharmaceuticals, Inc. | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe Asset: APL-2, Pegcetacoplan | Geographic Atrophy Secondary to Age-related Macular Degeneration | Due Dec 2026 | Q4 2025 2025-12-12 | Completed · awaiting
Updated 11mo ago
| NCT07214740 |
| Colgate Palmolive | Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ Model Asset: Fluoride free toothpaste in a chalk base | Demineralization +3 | Due Dec 2026 | Q4 2025 2025-12-11 | Completed · awaiting
Updated 9mo ago
| NCT07134231 |
| Eli Lilly and Company | A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Asset: Galcanezumab | Chronic Migraine | Due Dec 2026 | Q4 2025 2025-12-10 | Completed · awaiting
Updated 9mo ago
| NCT04616326 |
| Rose Research Center, LLC | Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders Asset: Nicoderm | Smoking Cessation +1 | Due Dec 2026 | Q4 2025 2025-12-09 | Completed · awaiting
Updated 9mo ago
| NCT06554873 |
| GlaxoSmithKline | A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old) Asset: rMenB+OMV NZ vaccine | Meningitis | Due Dec 2026 | Q4 2025 2025-12-08 | Completed · awaiting
Updated 7mo ago
| NCT06995430 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Asset: Cagrilintide | Obesity | Due Dec 2026 | Q4 2025 2025-12-08 | Completed · awaiting
Updated 9mo ago
| NCT06131437 |
| AbbVie | A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants | Facial Volume Deficit | Due Dec 2026 | Q4 2025 2025-12-05 | Completed · awaiting
Updated 11mo ago
| NCT05818709 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Asset: Survodutide | Obesity | Due Dec 2026 | Q4 2025 2025-12-03 | Completed · awaiting
Updated 11mo ago
| NCT06176365 |
| Immunome, Inc. | A Study of AL102 in Patients With Progressing Desmoid Tumors Asset: AL102 | Desmoid +1 | Due Dec 2026 | Q4 2025 2025-12-03 | Completed · awaiting
Updated 9mo ago
| NCT04871282 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | Due Dec 2026 | Q4 2025 2025-12-02 | Completed · awaiting
Updated 8mo ago
| NCT06066515 |
| BeiGene | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer Asset: Pamiparib capsule | Ovarian Cancer | Due Dec 2026 | Q4 2025 2025-12-01 | Completed · awaiting
Updated 8mo ago
| NCT03519230 |
| AbbVie | Open-label Trial in Parkinson's Disease (PD) Asset: Tavapadon | Parkinson Disease | Due Dec 2026 | Q4 2025 2025-12-01 | Completed · awaiting
Updated 11mo ago
| NCT04760769 |
| Apellis Pharmaceuticals, Inc. | Pegcetacoplan Long Term Safety and Efficacy Extension Study Asset: Pegcetacoplan | PNH | Due Nov 2026 | Q4 2025 2025-11-29 | Completed · awaiting
Updated 7mo ago
| NCT03531255 |
| GB002, Inc. | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) Asset: Placebo | Pulmonary Arterial Hypertension | Due Nov 2026 | Q4 2025 2025-11-27 | Completed · awaiting
Updated 7mo ago
| NCT05934526 |
| Vincentage Pharma Co., Ltd | A Research Study of VCT220 in Adult Chinese Participants With Obesity Asset: VCT220 | Obesity +1 | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 8mo ago
| NCT06939296 |
| Sanofi | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) Asset: Amlitelimab | Dermatitis Atopic | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 8mo ago
| NCT06181435 |
| Hutchmed | HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Asset: HMPL-523(300mg PO QD) | Warm Antibody Autoimmune Hemolytic Anemia | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 8mo ago
| NCT05535933 |
| Bristol-Myers Squibb | A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Asset: Mavacamten | Cardiomyopathy, Hypertrophic | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 11mo ago
| NCT06253221 |
| AbbVie | A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence Asset: BOTOX | Masseter Muscle Prominence | Due Nov 2026 | Q4 2025 2025-11-25 | Completed · awaiting
Updated 11mo ago
| NCT06387394 |
| AstraZeneca | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Asset: Baxdrostat | Uncontrolled Hypertension +1 | Due Nov 2026 | Q4 2025 2025-11-24 | Completed · awaiting
Updated 7mo ago
| NCT06344104 |
| AstraZeneca | Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China Asset: Nirsevimab | Lower Respiratory Tract Infection | Due Nov 2026 | Q4 2025 2025-11-24 | Completed · awaiting
Updated 7mo ago
| NCT05110261 |
| Colgate Palmolive | Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the Immediate Removal of Tooth Stains After a Single Brushing. Asset: Optic White Adv Sparkling White (2%HP) Toothpaste | Whitening | Due Nov 2026 | Q4 2025 2025-11-24 | Completed · awaiting
Updated 11mo ago
| NCT07276672 |
| Insmed Incorporated | Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex Asset: ALIS | Mycobacterium Infections, Nontuberculous | Due Nov 2026 | Q4 2025 2025-11-21 | Completed · awaiting
Updated 9mo ago
| NCT04677569 |
| CSL Behring | Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks Asset: CSL312 | Hereditary Angioedema | Due Nov 2026 | Q4 2025 2025-11-21 | Completed · awaiting
Updated 10mo ago
| NCT04739059 |
| Eli Lilly and Company | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Asset: Orforglipron | Obesity +1 | Due Nov 2026 | Q4 2025 2025-11-21 | Completed · awaiting
Updated 11mo ago
| NCT06584916 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Asset: Satralizumab | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 7mo ago
| NCT05271409 |
| Cutia Therapeutics（Wuxi）Co.,Ltd | A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) Asset: CU-20101 treatment for Moderate to Severe Glabellar Striae | Glabellar Frown Lines | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 9mo ago
| NCT06585696 |
| Amgen | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis Asset: Apremilast | Plaque Psoriasis | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 11mo ago
| NCT05565560 |
| AbbVie | A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants Asset: BOTOX | Masseter Muscle Prominence | Due Nov 2026 | Q4 2025 2025-11-20 | Completed · awaiting
Updated 11mo ago
| NCT06068855 |
| CSL Behring | CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema Asset: CSL312 | Hereditary Angioedema (HAE) | Due Nov 2026 | Q4 2025 2025-11-19 | Completed · awaiting
Updated 10mo ago
| NCT05819775 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes Mellitus | Due Nov 2026 | Q4 2025 2025-11-19 | Completed · awaiting
Updated 10mo ago
| NCT06065540 |
| Amgen | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine Asset: Erenumab Dose 1 | Migraine | Due Nov 2026 | Q4 2025 2025-11-19 | Completed · awaiting
Updated 11mo ago
| NCT03836040 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Asset: Ixekizumab | Psoriatic Arthritis +1 | Due Nov 2026 | Q4 2025 2025-11-18 | Completed · awaiting
Updated 10mo ago
| NCT06588296 |
| Vifor Fresenius Medical Care Renal… | Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects Asset: Patiromer Powder for Oral Suspension (Part A) | Hyperkalemia +1 | Due Nov 2026 | Q4 2025 2025-11-18 | Completed · awaiting
Updated 7mo ago
| NCT05136664 |
| F2G Ltd | Olorofim Aspergillus Infection Study Asset: Olorofim | Invasive Aspergillosis | Due Nov 2026 | Q4 2025 2025-11-18 | Completed · awaiting
Updated 10mo ago
| NCT05101187 |
| Janssen Research & Development, LLC | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis Asset: JNJ-77242113 | Plaque Psoriasis | Due Nov 2026 | Q4 2025 2025-11-17 | Completed · awaiting
Updated 7mo ago
| NCT06934226 |
| ModernaTX, Inc. | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age Asset: mRNA-1083 | COVID-19 +1 | Due Nov 2026 | Q4 2025 2025-11-17 | Completed · awaiting
Updated 11mo ago
| NCT06694389 |
| Sanofi Pasteur, a Sanofi Company | Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa Asset: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | Meningococcal Immunisation +1 | Due Nov 2026 | Q4 2025 2025-11-15 | Completed · awaiting
Updated 10mo ago
| NCT05794230 |
| Eli Lilly and Company | A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Asset: Galcanezumab | Episodic Migraine | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 10mo ago
| NCT03432286 |
| Eli Lilly and Company | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Asset: Retatrutide | Obesity +2 | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 10mo ago
| NCT05931367 |
| Sanofi | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Asset: Tolebrutinib | Primary Progressive Multiple Sclerosis | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 10mo ago
| NCT04458051 |
| Sanofi Pasteur, a Sanofi Company | Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers Asset: MenACYW conjugate vaccine | Meningococcal Immunisation +1 | Due Nov 2026 | Q4 2025 2025-11-14 | Completed · awaiting
Updated 11mo ago
| NCT06284915 |
| Zenas BioPharma (USA), LLC | A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease Asset: Obexelimab | IgG4 Related Disease | Due Nov 2026 | Q4 2025 2025-11-13 | Completed · awaiting
Updated 9mo ago
| NCT05662241 |
| Vertex Pharmaceuticals Incorporated | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia Asset: CTX001 | Beta-Thalassemia +4 | Due Nov 2026 | Q4 2025 2025-11-13 | Completed · awaiting
Updated 11mo ago
| NCT03655678 |
Upcoming readouts — next 12 months
· 300Industry Phase 3 trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| AstraZeneca | A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus | Active Not Recruiting | Q4 2026 2026-11-13 (est.) | Estimated · aging
Updated 8mo ago
| NCT06015737 |
| Achieve Life Sciences | Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes Asset: Cytisinicline | Vaping Cessation | Not Yet Recruiting | Q4 2026 2026-11-15 (est.) | Estimated · aging
Updated 9mo ago
| NCT07392125 |
| UCB Biopharma SRL | A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Asset: Zilucoplan | Generalized Myasthenia Gravis | Recruiting | Q4 2026 2026-11-16 (est.) | Estimated · aging
Updated 7mo ago
| NCT06055959 |
| CSL Behring | Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) Asset: BE1116 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Recruiting | Q4 2026 2026-11-18 (est.) | Estimated · aging
Updated 7mo ago
| NCT07094087 |
| Medicine Invention Design, Inc | Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | Active Not Recruiting | Q4 2026 2026-11-18 (est.) | Estimated · aging
Updated 7mo ago
| NCT05987956 |
| Sanofi | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis Asset: Frexalimab | Multiple Sclerosis | Active Not Recruiting | Q4 2026 2026-12-23 (est.) | Estimated · aging
Updated 9mo ago
| NCT06141486 |
| Hoffmann-La Roche | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis Asset: Afimkibart | Moderately to Severely Active Ulcerative Colitis | Active Not Recruiting | Q1 2027 2027-01-30 (est.) | Estimated · aging
Updated 7mo ago
| NCT06588855 |
| Hoffmann-La Roche | A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Asset: Afimkibart | Moderately to Severely Active Ulcerative Colitis | Active Not Recruiting | Q1 2027 2027-01-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT06589986 |
Unlock 292 more readouts · filter by sponsor, indication, and time window
From the briefs
All briefs →Plain-English deep dives on the mechanisms, targets and trials behind these readouts.
Can IL-23 Drugs for Crohn's Start at Home?
Some Crohn's drugs already start with injections or a pill, but most IL-23 drugs still begin with clinic or hospital infusions. AbbVie wants to change that for Skyrizi, after its AFFIRM trial showed that starting with injections works.
Approved Early, Proven Later? What Happens to Cancer Accelerated Approvals
The FDA can put a cancer drug on the market years early, on the promise that proof will follow. We checked all 219 oncology accelerated approvals on the FDA's own lists to see how often a drug with accelerated approval goes on to get full approval.
How to Read a Cancer Trial and Tell If Patients Live Longer
A cancer drug 'works.' But did patients live longer, or did a tumor just shrink? The answer is which endpoint the trial made its primary measure. Here is how to read it.
The Daraxonrasib Success Story
How RAS went from "undruggable" to Rasonque, the first RAS-targeted medicine to extend survival in pancreatic cancer, and the best reporting and science behind it.
Can an IBD Biologic Last Six Months?
Several companies want to stretch IBD antibodies from a shot every few weeks to one every three months, or even six. Keeping the drug in the blood that long is the easy part. Whether the disease stays controlled right up to the next dose is the hard part, and the bet the newest programs are making.
Does Blocking IL-17F Actually Matter?
Two of the newest PsA drugs block IL-17F as well as IL-17A; the older ones block only IL-17A. A plain walk through what the extra target actually buys: clear help on the skin, no proven help on the joints yet, and a fungal cost in the middle.
Methodology & caveats
Why this is harder than it looks
There is no single “readout date” on any public registry. A Phase 3 trial generates three different dated events, only one of which is registered:
- Primary completion date — last patient finishes the primary endpoint analysis. This is the only event published on ClinicalTrials.gov.
- Topline announcement — the company press release / 8-K that actually moves the stock. Typically lands 3–9 months after primary completion. Not registered anywhere structured.
- Results posted to CT.gov — full data uploaded to the registry. Mandated by FDAAA within 12 months of primary completion (often hits the deadline).
Most sponsor-supplied dates are ESTIMATED and can slip silently. Plenty of "active" trials haven't been touched on CT.gov in 12+ months — the date you see may be a stale ghost.
How we label every row
We anchor on CT.gov primary completion (the only public, structured signal) and combine date type (ACTUAL vs ESTIMATED) with the time since the sponsor last updated the trial record:
- Read out — results have been posted to ClinicalTrials.gov (definitive).
- Completed · awaiting — primary completion is ACTUAL but no results yet (topline often already announced; sponsor has 12 months under FDAAA to post).
- Estimated · fresh / aging / stale — sponsor estimate, with last-update freshness in 3 buckets (≤6 mo / 6–12 mo / >12 mo).
What we explicitly don't claim
We do not predict topline announcement dates and we do not score per-trial slip risk. Both would require SEC EDGAR full-text NCT linking and historical version snapshots — separate enrichments we've scoped but not built. Other free retail calendars conflate ACTUAL/ESTIMATED dates and don't flag staleness; we label them so you don't have to guess which dates are credible.
Coverage
Source: ClinicalTrials.gov v2 API. We list industry-sponsored Phase 3 trials with primary completion in the last 6 months or next 12+ months. Excluded: TERMINATED, WITHDRAWN, SUSPENDED. Phase 2 readouts are out of scope today (5x volume, separate sprint).